Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Competition Coming For Hemophilia Franchises, But Will Patients And Payers Embrace New Drugs?

Executive Summary

Roche's emicizumab, Alnylam's fitusiran and multiple gene therapies may soon steal market share from established clotting factors sold by Shire, Novo Nordisk and others, but safety is a key consideration for physicians and patients.


Related Content

Bayer To Ship Long-Acting Hemophilia Infusion Jivi In A Jiffy
CSL Looks Beyond Organic Growth To External Innovation
Non-Inhibitor Data Secure Roche's Competitive Position In Hemophilia A
Is Anemic Growth Sending Novo Nordisk After Global Blood Therapeutics?
Patient Death Casts Cloud Over Roche Emicizumab Hemophilia Trial
Shire's Record Year Bolstered By Baxalta, But Shows Across-The-Board Growth
Emicizumab Data Has Shire And Novo Looking Over Their Shoulders
Alnylam's Fitusiran Could Provide Comprehensive Hemophilia Therapy Option
Shire Backs Hemophilia Focus With Asset Updates, Irish iPATH Study
BioNotebook: Halozyme falters; Baxter acquires Chatham; Celgene buys Acceleron shares; and IPOs lose momentum


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts